RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Results from the ALTITUDE Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 13
SP 13
OP 13
DO 10.1177/155989771213005
UL http://mdc.sagepub.com/content/12/13/13.1.abstract
AB The addition of aliskiren, a novel direct renin inhibitor that lowers plasma renin activity, to standard therapy (an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker) did not improve outcomes for people with type 2 diabetes and renal impairment who are at high risk for cardiovascular and renal events. This finding is among the preliminary results of Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints [ALTITUDE; NCT00549757], which was stopped early in December 2011 because of futility and a high rate of adverse events in the aliskiren group.